Literature DB >> 22548951

Contribution of the dawn phenomenon to the fasting and postbreakfast hyperglycemia in type 1 diabetes treated with once-nightly insulin glargine.

Allen B King1, Dawn Clark, Gary S Wolfe.   

Abstract

OBJECTIVE: To observe the effect of the dawn phenomenon on basal glucose and postbreakfast hyperglycemia in patients with type 1 diabetes treated with once-nightly insulin glargine and premeal insulin lispro.
METHODS: In 49 study subjects consuming a fixed isocaloric (50% carbohydrate) diet of usual food, the insulin glargine dose was titrated from daily continuous glucose monitoring downloads to achieve a basal glucose goal of <130 mg/dL 4 hours after meals and during serial meal omissions but with fewer than 10% of readings at <70 mg/dL during 24 hours. Patients also performed self-monitoring of plasma glucose 7 times a day (before and 2 hours after each meal or omitted meal and at bedtime).
RESULTS: The target mean basal glucose level was achieved only during the non-dawn phenomenon period (1400 hours to 0400 hours). During the dawn phenomenon, the mean (standard deviation) basal glucose level increased from 118 (57) mg/dL at 0400 hours to 156 (67) mg/dL before the breakfast meal, a 32% increase (P = .00149). The mean self-monitored plasma glucose level with meal omission was 63.8% of that increase with a breakfast meal.
CONCLUSION: The fasting morning glucose concentration is considerably elevated because of the dawn phenomenon. Targeting insulin titration to this glucose level may result in excessive basal insulin dosing for the non-dawn phenomenon periods of the day. The dawn phenomenon is a large component of the postbreakfast hyperglycemia. Rather than increasing the morning premeal insulin bolus, consideration should be given to pretreating the earlier dawn phenomenon with an insulin pump with use of a variable basal insulin rate.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22548951     DOI: 10.4158/EP12042.OR

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  7 in total

Review 1.  Reassessment of insulin dosing guidelines in continuous subcutaneous insulin infusion treated type 1 diabetes.

Authors:  Allen Bennett King
Journal:  Curr Diab Rep       Date:  2014-06       Impact factor: 4.810

Review 2.  Insulin glargine 300 U/mL in the management of diabetes: clinical utility and patient perspectives.

Authors:  Bastiaan E de Galan
Journal:  Patient Prefer Adherence       Date:  2016-10-17       Impact factor: 2.711

3.  Effects of sodium-glucose cotransporter 2 inhibitors on hypoglycaemia in brittle diabetic patients with decreased endogenous insulin secretion.

Authors:  Susumu Ogawa; Kazuhiro Nako; Sadayoshi Ito
Journal:  Endocrinol Diabetes Metab       Date:  2018-12-01

4.  The impact of dusk phenomenon on total glucose exposure in Chinese people with type 2 diabetes.

Authors:  Yuxin Huang; Yuanyuan Xu; Jieyuzhen Qiu; Cuiping Jiang; Wen Tan; Xiaoming Tao; Qin Gu; Jiao Sun
Journal:  Medicine (Baltimore)       Date:  2021-04-02       Impact factor: 1.817

5.  The dawn phenomenon in type 2 diabetes: its association with glucose excursions and changes after oral glucose-lowering drugs.

Authors:  Jun-Sing Wang; I-Te Lee; Wen-Jane Lee; Shi-Dou Lin; Shih-Li Su; Shih-Te Tu; Shih-Yi Lin; Wayne Huey-Herng Sheu
Journal:  Ther Adv Chronic Dis       Date:  2021-08-10       Impact factor: 5.091

6.  The northeast glucose drift: Stratification of post-breakfast dysglycemia among predominantly Hispanic/Latino adults at-risk or with type 2 diabetes.

Authors:  Barua Souptik; Sabharwal Ashutosh; Glantz Namino; Conneely Casey; Larez Arianna; Bevier Wendy; Kerr David
Journal:  EClinicalMedicine       Date:  2021-12-20

Review 7.  A Review of Insulin-Dosing Formulas for Continuous Subcutaneous Insulin Infusion (CSII) for Adults with Type 1 Diabetes.

Authors:  Allen B King; Akio Kuroda; Munehide Matsuhisa; Todd Hobbs
Journal:  Curr Diab Rep       Date:  2016-09       Impact factor: 4.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.